The internationally active U.S. investment company BlackRock, with nine trillion U.S. dollars in assets under management, is taking a stake in the Swiss company Zur Rose, the parent company of DocMorris.
BlackRock has recently owned three percent of the share packages from DocMorris‘ parent company. According to the report, BlackRock has invested 100 million euros in Zur Rose, which has been listed on the stock exchange since 2017. BlackRock is the world’s largest asset manager, with which German customers have also invested 170 billion euros.
BlackRock is the third U.S. shareholder, after U.S. hedge funds Invesco and Fidelity, to enter the mail-order pharmacy Zur Rose in the drug distribution sector with three percent and more than three percent, respectively.
In 2017, the current public company went public after the Frey family of entrepreneurs became a major shareholder with its investment company Corisol a year earlier. At the time, Corisol acquired 22 percent of Zur Rose shares and invested 40 million Swiss francs. In 2020, Corisol finally exited, partly to make way for Luxembourg-based financial investor Ethenea and the Credit Suisse fund. They acquired more than three percent of the shares. The rest of the shares are shared by the Saudi royal family, which acquired shares for the second time, and major banks such as UBS and Norges Bank. Other financial investors include Portsea, JP Morgan, Wellington and T. Rowe Price and Acxit. Asset manager Patrick Schmitz-Morkramer also bought into pharmaceuticals manager and supply service provider Zur Rose.
Source: www.apotheke-adhoc.de